RE: Nivolumab6 Dec 2024 08:54
BOJO, in case of protein/small molecule drugs intravenous vs subcutaneous is a matter of convenience, of you can get them to work subcutaneously.
In the case of DNA drugs, it is a matter whether you want to target the muscle (better "factory" than skin but fewer dendritic cells) or the skin, to get to more dendritic cells.